Search for a trial

Validation and feasibility assessment of STAT-intraoperative-PTH measurement during total thyroidectomy to predict postoperative hypocalcaemia

The aim of this study is to evaluate the use of rapid IO-PTH measurement to predict post-thyroidectomy hypocalciemia.

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects with Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed after Prior VEGFR-Targeted Therapy

The objective of this study is to evaluate the effect of cabozantinib compared with placebo on PFS and ORR in subjects with RAI-refractory DTC who have progressed after prior VEGFR-targeted therapy.

The uptake of radioactive iodine before and after a low iodine diet in patients with differentiated thyroid carcinoma

Primary objective: 1. To compare the difference in thyroid uptake of a low tracer dose radioactive iodine (10 MBq 123I or 37 MBq 123I) (1a), in DTC patients after thyroidectomy, before and after a LID of 7 days (1b).Primary objective described in…

A prospective follow-up Intervention Study: Detection of Early Esophageal Cancer by Near-Infrared Fluorescence molecular Endoscopy using Bevacizumab-800CW

Primary:To evaluate the performance of FME with topical administration of Bevacizumab-800CW for detection of neoplasia in BE patients compared to HD-WLE to make an estimation of the diagnostic accuracy in terms of sensitivity and specificity in…

Improving Treatment Options for Somatostatin Type 2 Receptor Negative Neuroendocrine Tumor Patients

The aim of this prospective proof-of-concept study is to increase the expression of the SSTR2 in NET patients with negative or low expression to levels amenable for somatostatin analogue treatment through the use of epigenetic drugs.

In-vivo multispectral optoacoustic imaging of thyroid nodules

We aim to determine if in vivo MSOT can distinguish benign from malignant thyroid nodules by correlating and validating optoacoustic signals in vivo with pathology results.

A phase III multi-center, randomized, open-label study to evaluate the efficacy and safety of Lutathera in patients with Grade 2 and Grade 3 advanced GEP-NET

This study has been transitioned to CTIS with ID 2023-507443-10-00 check the CTIS register for the current data. The pivotal Phase III NETTER-1 study showed that Lutathera with best supportive care (30mg octreotide long-acting) provided a…